• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微流控法制备纳米凝胶作为替代三联转染试剂用于腺相关病毒载体的制造。

Microfluidic production of nanogels as alternative triple transfection reagents for the manufacture of adeno-associated virus vectors.

机构信息

Department of Pharmaceutics, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N 1AX, UK.

Department of Pharmacology, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N 1AX, UK.

出版信息

Nanoscale. 2023 Mar 23;15(12):5865-5876. doi: 10.1039/d2nr06401d.

DOI:10.1039/d2nr06401d
PMID:36866741
Abstract

Adeno-associated viral vectors (AAVs) have proved a mainstay in gene therapy, owing to their remarkable transduction efficiency and safety profile. Their production, however, remains challenging in terms of yield, the cost-effectiveness of manufacturing procedures and large-scale production. In this work, we present nanogels produced by microfluidics as a novel alternative to standard transfection reagents such as polyethylenimine-MAX (PEI-MAX) for the production of AAV vectors with comparable yields. Nanogels were formed at pDNA weight ratios of 1 : 1 : 2 and 1 : 1 : 3, of pAAV -plasmid, pDG9 capsid -plasmid and pHGTI helper plasmid respectively, where vector yields at a small scale showed no significant difference to those of PEI-MAX. Weight ratios of 1 : 1 : 2 showed overall higher titers than 1 : 1 : 3, where nanogels with nitrogen/phosphate ratios of 5 and 10 produced yields of ≈8.8 × 10 vg mL and ≈8.1 × 10 vg mL respectively compared to ≈1.1 × 10 vg mL for PEI-MAX. In larger scale production, optimised nanogels produced AAV at a titer of ≈7.4 × 10 vg mL, showing no statistical difference from that of PEI-MAX at ≈1.2 × 10 vg mL, indicating that equivalent titers can be achieved with easy-to-implement microfluidic technology at comparably lower costs than traditional reagents.

摘要

腺相关病毒载体(AAV)由于其显著的转导效率和安全特性,已成为基因治疗的主要手段。然而,它们的生产在产量、制造工艺的成本效益和大规模生产方面仍然具有挑战性。在这项工作中,我们提出了由微流体制备的纳米凝胶作为标准转染试剂(如聚乙烯亚胺-MAX(PEI-MAX))的替代物,用于生产具有可比产量的 AAV 载体。纳米凝胶在 pDNA 重量比为 1:1:2 和 1:1:3 的条件下形成,分别为 pAAV-质粒、pDG9 衣壳-质粒和 pHGTI 辅助质粒,小规模下的载体产量与 PEI-MAX 相比没有显著差异。重量比为 1:1:2 的总体表现出比 1:1:3 更高的滴度,其中氮/磷比为 5 和 10 的纳米凝胶分别产生约 8.8×10 vg mL 和约 8.1×10 vg mL 的产量,而 PEI-MAX 的产量约为 1.1×10 vg mL。在大规模生产中,优化后的纳米凝胶产生的 AAV 滴度约为 7.4×10 vg mL,与 PEI-MAX 的 1.2×10 vg mL 相比没有统计学差异,表明可以通过易于实施的微流控技术以可比传统试剂更低的成本获得等效的滴度。

相似文献

1
Microfluidic production of nanogels as alternative triple transfection reagents for the manufacture of adeno-associated virus vectors.微流控法制备纳米凝胶作为替代三联转染试剂用于腺相关病毒载体的制造。
Nanoscale. 2023 Mar 23;15(12):5865-5876. doi: 10.1039/d2nr06401d.
2
AAV2 production with optimized N/P ratio and PEI-mediated transfection results in low toxicity and high titer for in vitro and in vivo applications.采用优化的 N/P 比和 PEI 介导的转染进行 AAV2 生产,可降低毒性并提高体外和体内应用的滴度。
J Virol Methods. 2013 Nov;193(2):270-7. doi: 10.1016/j.jviromet.2013.06.008. Epub 2013 Jun 19.
3
Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale.大规模快速、简单且多功能的重组腺相关病毒载体的制造。
Hum Gene Ther. 2010 Oct;21(10):1259-71. doi: 10.1089/hum.2010.055.
4
Production of adeno-associated viral vector serotype 6 by triple transfection of suspension HEK293 cells at higher cell densities.悬浮 HEK293 细胞在较高细胞密度下通过三重转染生产腺相关病毒血清型 6。
Biotechnol J. 2023 Sep;18(9):e2300051. doi: 10.1002/biot.202300051. Epub 2023 Jul 2.
5
Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombinant adeno-associated virus vectors.使用线性聚乙烯亚胺转染哺乳动物细胞是生产重组腺相关病毒载体的一种简单有效的方法。
J Virol Methods. 2006 Dec;138(1-2):85-98. doi: 10.1016/j.jviromet.2006.07.024. Epub 2006 Sep 6.
6
Production of Recombinant Adeno-associated Virus Vectors Using Suspension HEK293 Cells and Continuous Harvest of Vector From the Culture Media for GMP FIX and FLT1 Clinical Vector.使用悬浮HEK293细胞生产重组腺相关病毒载体,并从培养基中连续收获载体以用于GMP FIX和FLT1临床载体。
Mol Ther. 2016 Feb;24(2):287-297. doi: 10.1038/mt.2015.187. Epub 2015 Oct 6.
7
High-titer, serum-free production of adeno-associated virus vectors by polyethyleneimine-mediated plasmid transfection in mammalian suspension cells.通过聚乙烯亚胺介导的质粒转染在哺乳动物悬浮细胞中进行高滴度、无血清腺相关病毒载体的生产。
Biotechnol Lett. 2007 Nov;29(11):1713-21. doi: 10.1007/s10529-007-9441-3. Epub 2007 Jul 17.
8
Detailed Protocol for the Novel and Scalable Viral Vector Upstream Process for AAV Gene Therapy Manufacturing.新型可扩展 AAV 基因治疗制造用病毒载体上游工艺的详细方案。
Hum Gene Ther. 2021 Aug;32(15-16):850-861. doi: 10.1089/hum.2020.054. Epub 2021 Mar 30.
9
Production of High-Yield Adeno Associated Vector Batches Using HEK293 Suspension Cells.使用 HEK293 悬浮细胞生产高产腺相关病毒批次。
J Vis Exp. 2024 Apr 26(206). doi: 10.3791/66532.
10
Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells.通过转染293悬浮细胞实现重组腺相关病毒2型的可扩展无血清生产。
J Virol Methods. 2007 Sep;144(1-2):32-40. doi: 10.1016/j.jviromet.2007.03.014. Epub 2007 Apr 30.

引用本文的文献

1
Recent Advances in Therapeutics and Manufacturing Processes of Recombinant Adeno-Associated Virus for the Treatment of Lung Diseases.用于治疗肺部疾病的重组腺相关病毒的治疗学和制造工艺的最新进展
Curr Gene Ther. 2025;25(3):237-256. doi: 10.2174/0115665232294935240826061311.
2
Nanogels: Recent Advances in Synthesis and Biomedical Applications.纳米凝胶:合成及生物医学应用的最新进展
Nanomaterials (Basel). 2024 Aug 1;14(15):1300. doi: 10.3390/nano14151300.
3
One-step flow synthesis of size-controlled polymer nanogels in a fluorocarbon microfluidic chip.
在碳氟化合物微流控芯片中一步法流动合成尺寸可控的聚合物纳米凝胶。
RSC Adv. 2024 Apr 8;14(16):11258-11265. doi: 10.1039/d4ra01956c. eCollection 2024 Apr 3.
4
Current avenues of gene therapy in Pompe disease.目前庞贝病的基因治疗途径。
Curr Opin Neurol. 2023 Oct 1;36(5):464-473. doi: 10.1097/WCO.0000000000001187. Epub 2023 Jul 19.